
Liang Jin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9902812/publications.pdf Version: 2024-02-01



LIANCIN

#	Article	IF	CITATIONS
1	Enhancing the Buccal Mucosal Delivery of Peptide and Protein Therapeutics. Pharmaceutical Research, 2015, 32, 1-21.	3.5	94
2	Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer's Disease. Journal of Alzheimer's Disease Reports, 2021, 5, 443-468.	2.2	59
3	Impact of P-Glycoprotein Inhibition and Lipopolysaccharide Administration on Blood-Brain Barrier Transport of Colistin in Mice. Antimicrobial Agents and Chemotherapy, 2011, 55, 502-507.	3.2	37
4	Brain Penetration of Colistin in Mice Assessed by a Novel High-Performance Liquid Chromatographic Technique. Antimicrobial Agents and Chemotherapy, 2009, 53, 4247-4251.	3.2	35
5	Species-Dependent Blood-Brain Barrier Disruption of Lipopolysaccharide: Amelioration by Colistin <i>In Vitro</i> and <i>In Vivo</i> . Antimicrobial Agents and Chemotherapy, 2013, 57, 4336-4342.	3.2	29
6	Pulmonary Delivery of the Kv1.3-Blocking Peptide HsTX1[R14A] for the Treatment of Autoimmune Diseases. Journal of Pharmaceutical Sciences, 2016, 105, 650-656.	3.3	27
7	Buccal mucosal delivery of a potent peptide leads to therapeutically-relevant plasma concentrations for the treatment of autoimmune diseases. Journal of Controlled Release, 2015, 199, 37-44.	9.9	26
8	Deferiprone protects the isolated atria from cardiotoxicity induced by doxorubicin. Acta Pharmacologica Sinica, 2006, 27, 1333-1339.	6.1	22
9	The flavonoid, 2′-methoxy-6-methylflavone, affords neuroprotection following focal cerebral ischaemia. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 1266-1282.	4.3	18
10	Effect of Systemic Infection Induced by Pseudomonas aeruginosa on the Brain Uptake of Colistin in Mice. Antimicrobial Agents and Chemotherapy, 2012, 56, 5240-5246.	3.2	17
11	Enabling Noninvasive Systemic Delivery of the Kv1.3-Blocking Peptide HsTX1[R14A] via the Buccal Mucosa. Journal of Pharmaceutical Sciences, 2016, 105, 2173-2179.	3.3	17
12	Effect of Permeation Enhancers on the Buccal Permeability of Nicotine: Ex vivo Transport Studies Complemented by MALDI MS Imaging. Pharmaceutical Research, 2018, 35, 70.	3.5	16
13	Quantitative Determination of Acyclovir in Aqueous Humor by LC-MS. Chromatographia, 2006, 63, 239-242.	1.3	15
14	Validation and Characterization of a Novel Peptide That Binds Monomeric and Aggregated Î ² -Amyloid and Inhibits the Formation of Neurotoxic Oligomers. Journal of Biological Chemistry, 2016, 291, 547-559.	3.4	15
15	The hyperpolarizationâ€activated cyclic nucleotideâ€gated 4 channel as a potential antiâ€seizure drug target. British Journal of Pharmacology, 2020, 177, 3712-3729.	5.4	14
16	Pioglitazone Increases Blood–Brain Barrier Expression of Fatty Acid-Binding Protein 5 and Docosahexaenoic Acid Trafficking into the Brain. Molecular Pharmaceutics, 2020, 17, 873-884.	4.6	13
17	Azone® Decreases the Buccal Mucosal Permeation of Diazepam in a Concentration-Dependent Manner via a Reservoir Effect. Journal of Pharmaceutical Sciences, 2014, 103, 1133-1141.	3.3	11
18	Preparation, characterization and in vivo pharmacodynamic evaluation of thymopentin loaded poly(lactide acid)/poly(lactide-co-glycolide acid) implants. International Journal of Pharmaceutics, 2010, 398, 123-129.	5.2	10

LIANG JIN

#	Article	IF	CITATIONS
19	Intestinal Permeability and Oral Absorption of Selected Drugs Are Reduced in a Mouse Model of Familial Alzheimer's Disease. Molecular Pharmaceutics, 2020, 17, 1527-1537.	4.6	10
20	Blockade of Microglial Kv1.3 Potassium Channels by the Peptide HsTX1[R14A] Attenuates Lipopolysaccharide-mediated Neuroinflammation. Journal of Pharmaceutical Sciences, 2022, 111, 638-647.	3.3	9
21	Evaluation of the Bioequivalence and Pharmacokinetics of Two Formulations of Rizatriptan after Single Oral Administration in Healthy Volunteers. Arzneimittelforschung, 2005, 55, 355-358.	0.4	7
22	Prolonged Plasma Exposure of the Kv1.3-Inhibitory Peptide HsTX1[R14A] by Subcutaneous Administration of a Poly(Lactic-co-Glycolic Acid) (PLGA) Microsphere Formulation. Journal of Pharmaceutical Sciences, 2021, 110, 1182-1188.	3.3	6
23	Lipopolysaccharide influences the plasma and brain pharmacokinetics of subcutaneously-administered HsTX1[R14A], a KV1.3-blocking peptide. Toxicon, 2021, 195, 29-36.	1.6	5
24	LC Determination and Pharmacokinetic Study of Sinomenine in Dog Plasma. Chromatographia, 2005, 62, 637-642.	1.3	4